Pomalyst® (pomalidomide): New important advice to minimise the risk of serious hepatotoxicity, interstitial lung disease and cardiac failure

Celgene Pte Ltd, Singapore, would like to inform healthcare professionals of important new safety information regarding Pomalyst® (pomalidomide). A European review concluded that pomalidomide can cause serious hepatotoxicity (acute hepatitis), interstitial lung disease and cardiac failure. The safety review was based on data from clinical trials, reports from clinical practice as well as published case reports. The local Package Insert and Patient Information Leaflet for Pomalyst® will be updated to include the above-mentioned newly identified risks. Please refer to the letter for more information.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.